TheFiscalFinder
Contractors / Mapp Biopharmaceutical, Inc.

Mapp Biopharmaceutical, Inc.

prime recipient of federal awards · UEI M9V9QTHR1H28 ✓ from source
$225.6M
obligated · FY2022
2
funding agencies
100%
from Health and Hum…
0%
single-source
2
states
97%
in California
5
industries

≈ computedSingle-source: 0% of this recipient’s $217M in federal contracts was awarded without competition (FPDS extent-competed codes); the rest was competed or unclassified. A high share often reflects sole-source or specialized work, not wrongdoing.

Where this money comes from

✓ from source
FUNDING AGENCIES
MAPP BIOPHARMACEUTICAL,
HHS
$0.2B
1 other agencies
$0B
Mapp Biopharmaceutical, Inc.
$0.2B
FY2022 obligated
band width = obligations · FY2022 · source: USASpending.gov

Biggest awards (total value)

Procurement of Therapeutics for Ebola, Sudan and Marburg Viruses
awarded 2022$188M
Contract 75A50122C00076
awarded 2022$110.9M

Total value over each award’s life, for awards active in FY2022: a decades-long contract can exceed one year’s obligations above.

What it does (NAICS / PSC)

Research and Development in Biotechnology (except Nanobiotechnology)$205.2M
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)$15.5M
Research and Development in the Social Sciences and Humanities$3.3M
Scientific Research - Combating Weapons of Mass Destruction$335.4K
Research and Development in Biotechnology$194.3K
Testing Laboratories and Services$88.8K

Where the work lands

California✓ from source$218.2M
Maryland✓ from source$88.8K

Competitors

No competitors computed.

Corporate family

Single registration: no combined family.

🔎
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are ✓ from source; figures we calculate are ≈ computed; links we infer (corporate parents, districts, competitors, connections between records) are ≈ inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.